Jul 10, 2026 08:00AM
Nov 6, 2025 08:00AM
Aug 14, 2025 08:00AM
Jul 31, 2025 02:26AM
Jul 3, 2025 06:49AM
Jul 2, 2025 07:45AM
Jul 2, 2025 07:45AM VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202
May 8, 2025 08:00AM
Apr 28, 2025 07:10AM
Apr 25, 2025 08:02AM
Apr 25, 2025 08:00AM
Jan 6, 2025 07:30AM
Jun 5, 2024 08:00AM
May 6, 2024 08:01AM VYNE Therapeutics (VYNE) Announces FDA Clearance of IND Application for VYN202
May 6, 2024 08:00AM
May 1, 2024 08:00AM
Feb 29, 2024 08:00AM
Feb 27, 2024 08:00AM
Jan 10, 2024 08:03AM
Jan 10, 2024 08:00AM
Oct 30, 2023 07:01AM VYNE Therapeutics (VYNE) Reports Positive Data from Phase 1b Trial of VYN201
Oct 30, 2023 07:00AM
Mar 30, 2023 07:45AM
Mar 30, 2023 07:45AM
Mar 9, 2023 04:01PM
Feb 15, 2023 08:05AM
Feb 15, 2023 08:00AM
Jan 9, 2023 04:01PM VYNE Therapeutics Announces First Vitiligo Patient Dosed in Phase 1a/b Clinical Trial of Novel BET Inhibitor VYN201
Nov 17, 2022 08:00AM
Jun 17, 2022 08:00AM
Apr 7, 2022 08:00AM
Apr 7, 2022 08:00AM
Mar 30, 2022 08:00AM
Mar 17, 2022 08:00AM
Mar 7, 2022 07:03AM VYNE Therapeutics (VYNE) Reports Positive Preclinical Data for Lead BET Inhibitor, VYN201, in Human Skin Model of Vitiligo
Mar 7, 2022 07:00AM
Jan 19, 2022 08:00AM
Jan 19, 2022 08:00AM
Jan 13, 2022 09:27AM
Jan 13, 2022 07:02AM
Jan 13, 2022 07:00AM
Nov 10, 2021 07:30AM VYNE Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
Nov 4, 2021 08:00AM
Oct 26, 2021 08:00AM
Oct 21, 2021 08:00AM
Oct 19, 2021 08:00AM
Oct 5, 2021 08:00AM
Sep 20, 2021 08:00AM
Sep 8, 2021 08:00AM VYNE Therapeutics to Present at the H.C. Wainwright Annual Investment Conference
Aug 12, 2021 07:30AM

325,893 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All